Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from SanBio Co ( (JP:4592) ) is now available.
SanBio Co., Ltd. has entered into a contract manufacturing agreement with JCR Pharmaceuticals for the trial production of AKUUGO® Suspension for Intracranial Implantation. This collaboration aims to explore future manufacturing opportunities to ensure stable production and diversify supply, particularly as SanBio seeks market expansion into the US and additional indications such as ischemic stroke. The agreement is expected to have minimal impact on the current fiscal year’s financial performance.
More about SanBio Co
SanBio Co., Ltd., founded in California in 2001, is a leader in regenerative medicine, focusing on the research, development, manufacturing, and sale of regenerative cell therapies. The company emphasizes treating central nervous system disorders with unmet medical needs. Its primary product, AKUUGO®, is approved for improving chronic motor paralysis related to traumatic brain injury.
YTD Price Performance: 0.0%
Average Trading Volume: 1,635
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $346.1M
For an in-depth examination of 4592 stock, go to TipRanks’ Stock Analysis page.
